FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009655655> ?p ?o ?g. }

• W2009655655 endingPage "57" @default.
• W2009655655 startingPage "56" @default.
• W2009655655 abstract "Rheumatoid arthritis is a chronic inflammatory disease affecting the synovial joints. It is characterised by persistent inflammation and destruction of bone and joints. It affects physical functioning and other dimensions of quality of life. Symptoms can be treated with analgesics and non-steroidal anti-inflammatory drugs, which block cyclo-oxygenase. The underlying disease process can be affected by drugs that block or reduce the concentration of cytokines, which are known as disease modifying antirheumatic drugs. These drugs are either conventional small molecules or biological molecules.The outcome of treatment for patients with rheumatoid arthritis has improved considerably during the past 20 years.1 People have speculated about the potential to reverse the disease for some time. Treatments that aim to induce remission have been called for since the start of the 1990s.2 Several approaches have been investigated, including step-up (adding one drug to another) and step-down (starting with a combination of drugs and withdrawing individual ones) regimens3 and giving three disease modifying antirheumatic drugs at the same time.4 All approaches have reduced inflammatory activity, delayed radiographic progression, and improved function and quality of life. However, only a few patients have achieved remission.5The benefits of cytokine blockers—for example, drugs that antagonise tumour necrosis factor (TNF)—have exceeded initial predictions. Blocking TNF was predicted to reduce symptoms, but to have little structural effect on bone and cartilage, as evidence from animal models indicated that interleukin-1 was a more important bone cytokine than TNF. Clinical studies have shown, however, that TNF blocking agents have long lasting benefit, particularly when combined with methotrexate, and have a major effect on bone damage.6 There is thus little doubt that the current most effective treatment for patients with rheumatoid arthritis is a combination of methotrexate and anti-TNF. But questions remain, such as whether all patients need this treatment to achieve an adequate response and whether it can be cost effective.The effects of TNF on remission have been assessed in two studies.7 8 The first found that 12 months of anti-TNF given early on in the disease process could produce remission, which was sustained one year after ceasing treatment.7 The second found that six months of TNF blockade showed only short term benefit.8Against this background, a single blinded pragmatic study with four treatment arms was started in the Netherlands, and the longer term data from this study have now been published.9 The first two arms tested the efficacy of conventional disease modifying antirheumatic drugs, with either a switching or step-up protocol, while the third and fourth arms compared anti-TNF plus methotrexate with combination treatment plus corticosteroids.A crucial feature of the study was that participants were all treated according to prespecified targets (treatment-to-target strategy)—initial drug regimens were adjusted if participants failed to reach low disease activity (disease activity score ≤2.4). By definition, all patients should have achieved the same end point, as they would have been switched to a biological treatment if they did not respond. The design allowed the investigators to analyse how frequently the strategy could succeed and to examine subsets of patients for the benefits of strategies such as switching or stepping down drugs.What were the main findings of this study? Firstly, by using an aggressive treatment-to-target strategy, remission can be achieved in about 40% of patients. Secondly, the trial arms that included anti-TNF reduced inflammation more rapidly, reduced long term disease activity more effectively, and had bigger structural benefits than those that did not. Thirdly, induction with anti-TNF allowed more patients to come off the biological treatment and remain in remission. Fourthly, the escalating monotherapy arms (which measured the likelihood of a good response to individual agents) showed that while around 30% of patients started on methotrexate responded well, subsequent responses to further conventional disease modifying antirheumatic drugs were rare. Thus, most patients who fail methotrexate monotherapy will benefit from a direct switch to anti-TNF plus methotrexate, rather than trying other conventional antirheumatic drug regimens.These long term data confirm the success of the treatment-to-target strategy, which has improved outcome in other pragmatic trials with conventional disease modifying antirheumatic drugs.10 Furthermore, anti-TNF plus methotrexate was the most effective and least toxic treatment.Another interesting message to come out of the study relates to prognosis. Patients entered into this study had established early rheumatoid arthritis and a high proportion had structural damage, indicating disease with a relatively poor prognosis. It is interesting that patients who declined entry into the study, and mostly had milder disease at baseline (and should therefore have had a better outcome), ended up doing much worse than the included patients (F Breedveld, personal communication, 2007). One lesson is that if patients with a poor prognosis could be identified early, then they would be the ones most likely to benefit from more aggressive approaches.Data suggest that patients with a poor prognosis can be identified by a combination of features including a high acute phase response, autoantibodies to rheumatoid factor or cyclic citrullinated peptides (or both), and evidence of radiological erosions at baseline. By using more sensitive imaging techniques, it might be possible to identify more people at high risk of a severe disease course.11Are we now in a position to recommend that patients with a poor prognosis should receive anti-TNF as first line treatment? If the cost of the drugs was minimal, the only relevant comparator would be combination regimens with corticosteroids and methotrexate as the anchoring drugs. Cost effectiveness analyses are under way and will influence how widespread such an approach is likely to be.The success of the treatment-to-target strategy supports its use in clinical practice whenever possible. The data also suggest that patients with rheumatoid arthritis can achieve remission, but for them to cease treatment and remain in remission they must be treated early on in the disease process.7 12 However, sufficient uncertainty exists to warrant further double blinded trials and analyses of their costs." @default.
• W2009655655 created "2016-06-24" @default.
• W2009655655 creator A5018678002 @default.
• W2009655655 creator A5035671675 @default.
• W2009655655 date "2007-07-12" @default.
• W2009655655 modified "2023-10-16" @default.
• W2009655655 title "Treating rheumatoid arthritis" @default.
• W2009655655 cites W1998091844 @default.
• W2009655655 cites W2003284223 @default.
• W2009655655 cites W2005429018 @default.
• W2009655655 cites W2014368601 @default.
• W2009655655 cites W2080638211 @default.
• W2009655655 cites W2098293486 @default.
• W2009655655 cites W2134171514 @default.
• W2009655655 cites W2156712409 @default.
• W2009655655 cites W2158392523 @default.
• W2009655655 cites W2163938114 @default.
• W2009655655 cites W2418970185 @default.
• W2009655655 cites W4242155593 @default.
• W2009655655 doi "https://doi.org/10.1136/bmj.39265.679375.80" @default.
• W2009655655 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1914503" @default.
• W2009655655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17626917" @default.
• W2009655655 hasPublicationYear "2007" @default.
• W2009655655 type Work @default.
• W2009655655 sameAs 2009655655 @default.
• W2009655655 citedByCount "10" @default.
• W2009655655 countsByYear W20096556552012 @default.
• W2009655655 countsByYear W20096556552013 @default.
• W2009655655 countsByYear W20096556552015 @default.
• W2009655655 crossrefType "journal-article" @default.
• W2009655655 hasAuthorship W2009655655A5018678002 @default.
• W2009655655 hasAuthorship W2009655655A5035671675 @default.
• W2009655655 hasBestOaLocation W20096556552 @default.
• W2009655655 hasConcept C126322002 @default.
• W2009655655 hasConcept C16005928 @default.
• W2009655655 hasConcept C2522767166 @default.
• W2009655655 hasConcept C2777077863 @default.
• W2009655655 hasConcept C2777575956 @default.
• W2009655655 hasConcept C41008148 @default.
• W2009655655 hasConcept C71924100 @default.
• W2009655655 hasConceptScore W2009655655C126322002 @default.
• W2009655655 hasConceptScore W2009655655C16005928 @default.
• W2009655655 hasConceptScore W2009655655C2522767166 @default.
• W2009655655 hasConceptScore W2009655655C2777077863 @default.
• W2009655655 hasConceptScore W2009655655C2777575956 @default.
• W2009655655 hasConceptScore W2009655655C41008148 @default.
• W2009655655 hasConceptScore W2009655655C71924100 @default.
• W2009655655 hasIssue "7610" @default.
• W2009655655 hasLocation W20096556551 @default.
• W2009655655 hasLocation W20096556552 @default.
• W2009655655 hasLocation W20096556553 @default.
• W2009655655 hasLocation W20096556554 @default.
• W2009655655 hasOpenAccess W2009655655 @default.
• W2009655655 hasPrimaryLocation W20096556551 @default.
• W2009655655 hasRelatedWork W2082406232 @default.
• W2009655655 hasRelatedWork W2156283049 @default.
• W2009655655 hasRelatedWork W2316954211 @default.
• W2009655655 hasRelatedWork W2326094713 @default.
• W2009655655 hasRelatedWork W2427075784 @default.
• W2009655655 hasRelatedWork W2617939361 @default.
• W2009655655 hasRelatedWork W2748952813 @default.
• W2009655655 hasRelatedWork W2761967325 @default.
• W2009655655 hasRelatedWork W2899084033 @default.
• W2009655655 hasRelatedWork W4210646529 @default.
• W2009655655 hasVolume "335" @default.
• W2009655655 isParatext "false" @default.
• W2009655655 isRetracted "false" @default.
• W2009655655 magId "2009655655" @default.
• W2009655655 workType "article" @default.